Hypothesis

Patients whose Zone 3 hepatocytes already exhibit elevated AMPK, Nrf2, or autophagy signaling before treatment are the subset that will achieve NASH resolution with metabolic therapies (e.g., semaglutide, lanifibranor). Conversely, patients with low basal stress‑pathway activation will not benefit because their cells lack the threat‑responsive signaling required to transduce therapeutic cues.

Rationale

Hormetic pathways are damage‑responsive, not constitutive, as shown by nutrient‑sensing modulation of mitochondrial phenotypes across the liver lobule[https://doi.org/10.1101/2023.04.13.536717]. Zone 3 hepatocytes operate under chronic hypoxia, high CYP450 load, and oxidative stress, making them a natural barometer of intracellular threat perception. Senescent Zone 3 cells display mitochondrial dysfunction and reduced metabolic capacity[https://doi.org/10.1038/ncomms15691], indicating that stress‑pathway activation correlates with functional decline but also with a heightened state of alertness that enables rapid adaptive responses.

If AMPK/Nrf2/autophagy act as threat detectors, then therapeutic agents that rely on these sensors (e.g., AMPK activators, Nrf2 inducers, autophagy enhancers) will only be effective in cells where the detectors are already engaged. This reframes hormetic pathways from direct longevity effectors to stratification biomarkers.

Novel Mechanistic Insight

Persistent HIF‑1α stabilization in Zone 3 hepatocytes remodels chromatin at stress‑response gene promoters, increasing accessibility for transcriptional co‑activators such as CBP/p300. This epigenetic priming creates a "ready‑state" whereby downstream effectors of AMPK/Nrf2 can be rapidly amplified by therapeutic signals. In the absence of HIF‑1α‑driven priming, the same therapeutic stimulus fails to recruit sufficient transcriptional machinery, resulting in muted metabolic rescue.

Testable Predictions

1. Baseline hepatic AMPK‑pThr172, Nrf2 nuclear translocation, or LC3‑II/I ratio (measured by biopsy or a hepatocyte‑specific PET tracer) will positively correlate with NASH resolution after 48 weeks of semaglutide or lanifibranor therapy.
2. Pharmacological induction of a mild, reversible stress (e.g., intermittent hypoxia or low‑dose rotenone) prior to therapy will increase baseline stress‑pathway activation and improve therapeutic response rates in patients who initially had low activation.
3. Blocking HIF‑1α in Zone 3 hepatocytes (using a liver‑targeted siRNA) will abolish the correlation between baseline stress‑pathway activation and therapeutic benefit, confirming the epigenetic priming mechanism.

Experimental Design

• Cohort: 200 treatment‑naïve NAFLD/NASH patients undergoing baseline liver biopsy.
• Stratification: Biopsies quantified for AMPK‑pThr172, Nrf2 nuclear intensity, LC3‑II/I, and HIF‑1α target gene expression (e.g., VEGFA, GLUT1). Patients divided into high vs. low activation groups (median split).
• Intervention: Random 1:1 to semaglutide 2.4 mg weekly or placebo for 48 weeks.
• Primary Outcome: NASH resolution (NAS ≤1, no worsening of fibrosis) assessed by central pathology.
• Secondary Outcomes: Change in MRI‑PDFF, ALT, and fibrosis stage.
• Mechanistic Sub‑Study: In a subset (n=30), administer a 2‑week course of intermittent hypoxia (12 % O₂, 4 h/day) before randomization to test priming effect.

Potential Pitfalls & Mitigation

Biopsy variability could misclassify activation status; using multiple cores and digital image analysis reduces sampling error. Off‑target effects of hypoxia preconditioning will be monitored via systemic oxygen saturation and lactate levels. If baseline activation fails to predict outcome, the hypothesis that hormetic pathways are purely threat‑responsive would be falsified, suggesting alternative mechanisms (e.g., independent drug pharmacokinetics) dominate therapeutic response.